196 related articles for article (PubMed ID: 22268372)
41. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
[TBL] [Abstract][Full Text] [Related]
42. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
43. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice.
Bover J; Perez R; Molina M; Benavides B; Ariza F; Miguel JL; Tornero F; Torregrosa JV;
Nephron Clin Pract; 2011; 118(2):c109-21. PubMed ID: 21150219
[TBL] [Abstract][Full Text] [Related]
44. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
Komaba H; Koizumi M; Tanaka H; Takahashi H; Sawada K; Kakuta T; Fukagawa M
Nephrol Dial Transplant; 2012 May; 27(5):1967-9. PubMed ID: 22140124
[TBL] [Abstract][Full Text] [Related]
45. [Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?].
Arenas MD; Rebollo P; Alvarez-Ude F; Prieto L; Gil MT; Malek T; Moledous A; Núñez C
Nefrologia; 2008; 28(5):511-6. PubMed ID: 18816209
[TBL] [Abstract][Full Text] [Related]
46. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
47. "Real-World" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study.
Vervloet M; Bencova V; Malberti F; Ashman N; Os I; Saha H; Ureña P; Zitt E; Rix M; Ryba M; Fouque D; Dehmel B; Petavy F; Jacobson SH
Clin Nephrol; 2010 Sep; 74(3):198-208. PubMed ID: 20860904
[TBL] [Abstract][Full Text] [Related]
48. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
[TBL] [Abstract][Full Text] [Related]
49. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
McManus C; Oh A; Lee JA; Hur C; Kuo JH
Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
52. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
53. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
55. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
56. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
Yousaf F; Charytan C
Ren Fail; 2014 Feb; 36(1):131-8. PubMed ID: 24060145
[TBL] [Abstract][Full Text] [Related]
57. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
58. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
59. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Tominaga Y; Matsuoka S; Uno N; Sato T
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
[TBL] [Abstract][Full Text] [Related]
60. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
